Seelos Therapeutics Ownership 2024 | Who Owns Seelos Therapeutics Now?

Overview RevenueFinancials Chart

Institutional Ownership

20.56%

Insider Ownership

0.49%

Retail Ownership

78.95%

Institutional Holders

75.00

Seelos Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GENDELL JEFFREY L	4.77%	0.33%	5,068,020	159,295	3.25%	3,503,015,000	Mar 31, 2023
VANGUARD GROUP INC	4.72%	0.00%	5,016,741	-	-	3,467,571,000	Mar 31, 2023
BLACKROCK INC.	1.56%	-	1,662,058	-124,552	-6.97%	1,148,814,000	Mar 31, 2023
MIRAE ASSET GLOBAL INVESTMENTS CO., LTD.	1.36%	0.00%	1,443,459	210,996	17.12%	997,719,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	1.07%	0.00%	1,138,001	22,118	1.98%	786,586,000	Mar 31, 2023
UNIPLAN INVESTMENT COUNSEL, INC.	1.06%	0.05%	1,126,815	-50,695	-4.31%	778,000	Mar 31, 2023
WEALTH EFFECTS LLC	0.90%	0.34%	956,046	956,046	100.00%	660,819,000	Mar 31, 2023
MAI CAPITAL MANAGEMENT	0.87%	0.01%	927,422	-94,586	-9.25%	641,034,000	Mar 31, 2023
MODERA WEALTH MANAGEMENT, LLC	0.82%	0.02%	871,505	-	-	602,385,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.59%	0.00%	624,862	-123,123	-16.46%	432,000	Mar 31, 2023
ADVISORSHARES INVESTMENTS LLC	0.38%	0.09%	399,133	26,050	6.98%	275,881,000	Mar 31, 2023
MORGAN STANLEY	0.33%	-	349,398	-1,937	-0.55%	241,503,000	Mar 31, 2023
GROUP ONE TRADING, L.P.	0.30%	0.00%	323,326	-963,863	-74.88%	223,483,000	Mar 31, 2023
STATE STREET CORP	0.30%	-	314,405	-	-	217,317,000	Mar 31, 2023
SIMPLEX TRADING, LLC	0.22%	0.00%	234,800	-86,700	-26.97%	162,000	Mar 31, 2023
NORTHERN TRUST CORP	0.18%	-	196,182	12,207	6.64%	135,601,000	Mar 31, 2023
DAVENPORT & CO LLC	0.13%	0.00%	135,500	-	-	93,658,000	Mar 31, 2023
STRATEGIC FAMILY WEALTH COUNSELORS, L.L.C.	0.11%	0.04%	112,000	112,000	100.00%	77,415,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.09%	-	100,300	-53,300	-34.70%	69,207,000	Mar 31, 2023
1492 CAPITAL MANAGEMENT LLC	0.09%	0.04%	98,061	-	-	67,780,000	Mar 31, 2023

Seelos Therapeutics's largest institutional shareholder is GENDELL JEFFREY L, holding 4.77% of the company's total share outstanding, currently valued at $3.50B. The top 10 institutional shareholders own together 17.71% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WEALTH EFFECTS LLC	0.90%	0.34%	956,046	956,046	100.00%	660,819,000	Mar 31, 2023
GENDELL JEFFREY L	4.77%	0.33%	5,068,020	159,295	3.25%	3,503,015,000	Mar 31, 2023
ADVISORSHARES INVESTMENTS LLC	0.38%	0.09%	399,133	26,050	6.98%	275,881,000	Mar 31, 2023
UNIPLAN INVESTMENT COUNSEL, INC.	1.06%	0.05%	1,126,815	-50,695	-4.31%	778,000	Mar 31, 2023
1492 CAPITAL MANAGEMENT LLC	0.09%	0.04%	98,061	-	-	67,780,000	Mar 31, 2023
STRATEGIC FAMILY WEALTH COUNSELORS, L.L.C.	0.11%	0.04%	112,000	112,000	100.00%	77,415,000	Mar 31, 2023
MODERA WEALTH MANAGEMENT, LLC	0.82%	0.02%	871,505	-	-	602,385,000	Mar 31, 2023
ASSET MANAGEMENT CORP /IL/ /ADV	0.04%	0.02%	40,500	40,500	100.00%	27,994,000	Mar 31, 2023
SOVEREIGN FINANCIAL GROUP, INC.	0.07%	0.02%	75,000	-	-	51,840,000	Mar 31, 2023
MAI CAPITAL MANAGEMENT	0.87%	0.01%	927,422	-94,586	-9.25%	641,034,000	Mar 31, 2023
CARMICHAEL HILL & ASSOCIATES, INC.	0.02%	0.01%	21,000	10,000	90.91%	14,516,000	Mar 31, 2023
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC	0.06%	0.01%	68,300	68,300	100.00%	47,209,000	Mar 31, 2023
TRUST CO OF TOLEDO NA /OH/	0.05%	0.01%	55,000	55,000	100.00%	38,016,000	Mar 31, 2023
WEALTHPLAN PARTNERS, LLC	0.07%	0.01%	73,693	-4,800	-6.12%	50,937,000	Mar 31, 2023
DELTA FINANCIAL GROUP, INC.	0.02%	0.01%	20,000	-	-	14,000	Mar 31, 2023
FIRST HEARTLAND CONSULTANTS, INC.	0.03%	0.00%	29,190	-1,100	-3.63%	20,176,000	Mar 31, 2023
NEWBRIDGE FINANCIAL SERVICES GROUP, INC.	0.01%	0.00%	8,000	-	-	5,530,000	Mar 31, 2023
CREWE ADVISORS LLC	0.03%	0.00%	27,777	-	-	19,200,000	Mar 31, 2023
MIRAE ASSET GLOBAL INVESTMENTS CO., LTD.	1.36%	0.00%	1,443,459	210,996	17.12%	997,719,000	Mar 31, 2023
UNITED BANK	0.02%	0.00%	26,200	-	-	18,109,000	Mar 31, 2023

The largest Seelos Therapeutics shareholder by % of total assets is WEALTH EFFECTS LLC. The company owns 956.05K shares of Seelos Therapeutics (SEEL), representing 0.34% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WEALTH EFFECTS LLC	0.90%	0.34%	956,046	956,046	100.00%	660,819,000	Mar 31, 2023
MIRAE ASSET GLOBAL INVESTMENTS CO., LTD.	1.36%	0.00%	1,443,459	210,996	17.12%	997,719,000	Mar 31, 2023
GENDELL JEFFREY L	4.77%	0.33%	5,068,020	159,295	3.25%	3,503,015,000	Mar 31, 2023
STRATEGIC FAMILY WEALTH COUNSELORS, L.L.C.	0.11%	0.04%	112,000	112,000	100.00%	77,415,000	Mar 31, 2023
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC	0.06%	0.01%	68,300	68,300	100.00%	47,209,000	Mar 31, 2023
TRUST CO OF TOLEDO NA /OH/	0.05%	0.01%	55,000	55,000	100.00%	38,016,000	Mar 31, 2023
ASSET MANAGEMENT CORP /IL/ /ADV	0.04%	0.02%	40,500	40,500	100.00%	27,994,000	Mar 31, 2023
ADVISORSHARES INVESTMENTS LLC	0.38%	0.09%	399,133	26,050	6.98%	275,881,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	1.07%	0.00%	1,138,001	22,118	1.98%	786,586,000	Mar 31, 2023
JPMORGAN CHASE & CO	0.02%	-	20,016	20,016	100.00%	14,000,000	Mar 31, 2023
JANE STREET GROUP, LLC	0.02%	-	18,283	18,283	100.00%	12,637,000	Mar 31, 2023
WOLVERINE TRADING, LLC	0.04%	0.00%	47,100	15,900	50.96%	33,000	Mar 31, 2023
INTEGRATED WEALTH CONCEPTS LLC	0.01%	0.00%	14,625	14,625	100.00%	10,000	Mar 31, 2023
NORTHERN TRUST CORP	0.18%	-	196,182	12,207	6.64%	135,601,000	Mar 31, 2023
SIMPLICITY SOLUTIONS, LLC	0.01%	0.00%	10,000	10,000	100.00%	6,912,000	Mar 31, 2023
CARMICHAEL HILL & ASSOCIATES, INC.	0.02%	0.01%	21,000	10,000	90.91%	14,516,000	Mar 31, 2023
TOCQUEVILLE ASSET MANAGEMENT L.P.	0.05%	0.00%	58,000	3,000	5.45%	40,090,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	0.00%	-	3,923	1,825	86.99%	2,711,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.00%	-	1,710	1,710	100.00%	1,000	Mar 31, 2023
VENTURI WEALTH MANAGEMENT, LLC	0.00%	0.00%	1,600	1,600	100.00%	1,106,000	Mar 31, 2023

As of Mar 31 2023, Seelos Therapeutics's largest institutional buyer is WEALTH EFFECTS LLC. The company purchased 956.05K stocks of SEEL, valued at $660.82M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
GROUP ONE TRADING, L.P.	0.30%	0.00%	323,326	-963,863	-74.88%	223,483,000	Mar 31, 2023
OASIS MANAGEMENT CO LTD.	-	-	-	-850,000	-100.00%	-	Mar 31, 2023
GROUP ONE TRADING, L.P.	0.09%	0.00%	90,500	-327,400	-78.34%	62,553,000	Mar 31, 2023
GROUP ONE TRADING, L.P.	0.05%	0.00%	51,600	-317,600	-86.02%	35,666,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.07%	-	78,100	-163,500	-67.67%	53,983,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.04%	-	45,900	-134,200	-74.51%	31,671,000	Mar 31, 2023
BLACKROCK INC.	1.56%	-	1,662,058	-124,552	-6.97%	1,148,814,000	Mar 31, 2023
MILLENNIUM MANAGEMENT LLC	0.59%	0.00%	624,862	-123,123	-16.46%	432,000	Mar 31, 2023
GSA CAPITAL PARTNERS LLP	-	-	-	-105,050	-100.00%	-	Mar 31, 2023
MAI CAPITAL MANAGEMENT	0.87%	0.01%	927,422	-94,586	-9.25%	641,034,000	Mar 31, 2023
SIMPLEX TRADING, LLC	0.22%	0.00%	234,800	-86,700	-26.97%	162,000	Mar 31, 2023
WEALTHPLAN INVESTMENT MANAGEMENT, LLC	-	-	-	-78,493	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-67,331	-100.00%	-	Mar 31, 2023
SIMPLEX TRADING, LLC	0.00%	-	3,000	-64,000	-95.52%	2,000	Mar 31, 2023
CITADEL ADVISORS LLC	0.02%	-	18,500	-58,500	-75.97%	12,787,000	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.09%	-	100,300	-53,300	-34.70%	69,207,000	Mar 31, 2023
UNIPLAN INVESTMENT COUNSEL, INC.	1.06%	0.05%	1,126,815	-50,695	-4.31%	778,000	Mar 31, 2023
MERIT FINANCIAL GROUP, LLC	-	-	-	-50,000	-100.00%	-	Mar 31, 2023
EXCHANGE TRADED CONCEPTS, LLC	-	-	-	-42,657	-100.00%	-	Mar 31, 2023
VIRTU FINANCIAL LLC	-	-	-	-34,534	-100.00%	-	Mar 31, 2023

As of Mar 31 2023, Seelos Therapeutics's biggest institutional seller is GROUP ONE TRADING, L.P.. The company sold -0.96M shares of SEEL, valued at $223.48M.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WEALTH EFFECTS LLC	0.90%	0.34%	956,046	956,046	100.00%	660,819,000	Mar 31, 2023
STRATEGIC FAMILY WEALTH COUNSELORS, L.L.C.	0.11%	0.04%	112,000	112,000	100.00%	77,415,000	Mar 31, 2023
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC	0.06%	0.01%	68,300	68,300	100.00%	47,209,000	Mar 31, 2023
TRUST CO OF TOLEDO NA /OH/	0.05%	0.01%	55,000	55,000	100.00%	38,016,000	Mar 31, 2023
ASSET MANAGEMENT CORP /IL/ /ADV	0.04%	0.02%	40,500	40,500	100.00%	27,994,000	Mar 31, 2023
JPMORGAN CHASE & CO	0.02%	-	20,016	20,016	100.00%	14,000,000	Mar 31, 2023
JANE STREET GROUP, LLC	0.02%	-	18,283	18,283	100.00%	12,637,000	Mar 31, 2023
INTEGRATED WEALTH CONCEPTS LLC	0.01%	0.00%	14,625	14,625	100.00%	10,000	Mar 31, 2023
SIMPLICITY SOLUTIONS, LLC	0.01%	0.00%	10,000	10,000	100.00%	6,912,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.00%	-	1,710	1,710	100.00%	1,000	Mar 31, 2023
VENTURI WEALTH MANAGEMENT, LLC	0.00%	0.00%	1,600	1,600	100.00%	1,106,000	Mar 31, 2023
AMERITAS ADVISORY SERVICES, LLC	0.00%	-	466	466	100.00%	326,000	Mar 31, 2023
US BANCORP \DE\	0.00%	-	100	100	100.00%	69,000	Mar 31, 2023

Seelos Therapeutics's largest new institutional shareholder by number of shares is WEALTH EFFECTS LLC, purchased 956.05K shares, valued at $660.82M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
OASIS MANAGEMENT CO LTD.	-	-	-	-850,000	-100.00%	-	Mar 31, 2023
GSA CAPITAL PARTNERS LLP	-	-	-	-105,050	-100.00%	-	Mar 31, 2023
WEALTHPLAN INVESTMENT MANAGEMENT, LLC	-	-	-	-78,493	-100.00%	-	Mar 31, 2023
SUSQUEHANNA INTERNATIONAL GROUP, LLP	-	-	-	-67,331	-100.00%	-	Mar 31, 2023
MERIT FINANCIAL GROUP, LLC	-	-	-	-50,000	-100.00%	-	Mar 31, 2023
EXCHANGE TRADED CONCEPTS, LLC	-	-	-	-42,657	-100.00%	-	Mar 31, 2023
VIRTU FINANCIAL LLC	-	-	-	-34,534	-100.00%	-	Mar 31, 2023
CITIZENS FINANCIAL GROUP INC/RI	-	-	-	-30,500	-100.00%	-	Mar 31, 2023
HIGHTOWER ADVISORS, LLC	-	-	-	-21,588	-100.00%	-	Mar 31, 2023
CITADEL ADVISORS LLC	-	-	-	-9,011	-100.00%	-	Mar 31, 2023
CUTLER GROUP LLC / CA	-	-	-	-1,800	-100.00%	-	Mar 31, 2023

Seelos Therapeutics's largest sold out institutional shareholder by shares sold is OASIS MANAGEMENT CO LTD., sold -0.85M shares, valued at -, as of undefined.

Seelos Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
AdvisorShares Trust	0.15%	621,317	-	-	Mar 28, 2024
AdvisorShares Trust	0.12%	462,694	281,435	155.27%	Mar 28, 2024
VANGUARD INDEX FUNDS	0.01%	4,991,013	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.01%	1,072,616	-	-	Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS	0.00%	73,139	-	-	Mar 31, 2024
VANGUARD INDEX FUNDS	0.00%	280,866	10,966	4.06%	Mar 31, 2024
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC	0.00%	2,802	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	43,701	18,135	70.93%	Feb 29, 2024
Guggenheim Active Allocation Fund	0.00%	585	-	-	Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS	0.00%	2,437	-	-	Mar 31, 2024
COLLEGE RETIREMENT EQUITIES FUND	0.00%	17,556	-	-	Mar 31, 2024
Guggenheim Active Allocation Fund	0.00%	19	-	-	Feb 29, 2024
Blackstone Alternative Investment Funds	0.00%	30	-	-	Mar 31, 2024

Seelos Therapeutics's largest mutual fund holder by % of total assets is "AdvisorShares Trust", owning 621.32K shares, compromising 0.15% of its total assets.

Seelos Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 23	75	1.35%
31 Dec, 22	74	1.37%
30 Sep, 22	73	1.39%
30 Jun, 22	72	-13.25%
31 Mar, 22	83	-7.78%
31 Dec, 21	90	-13.46%
30 Sep, 21	104	7.22%
30 Jun, 21	97	40.58%
31 Mar, 21	69	155.56%
31 Dec, 20	27	8.00%
30 Sep, 20	25	-3.85%
30 Jun, 20	26	23.81%
31 Mar, 20	21	50.00%
31 Dec, 19	14	-30.00%
30 Sep, 19	20	33.33%
30 Jun, 19	15	25.00%
31 Mar, 19	12	1100.00%
31 Dec, 18	1	-

As of 31 Mar 23, 75 institutions are holding Seelos Therapeutics's shares, representing an increase of 1.35% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 23	21,865,016	-4.31%
31 Dec, 22	22,850,203	-16.02%
30 Sep, 22	27,207,513	-13.12%
30 Jun, 22	31,315,916	-20.63%
31 Mar, 22	39,455,693	-2.56%
31 Dec, 21	40,494,190	-0.78%
30 Sep, 21	40,811,743	-0.07%
30 Jun, 21	40,838,763	63.25%
31 Mar, 21	25,016,141	233.72%
31 Dec, 20	7,496,228	50.30%
30 Sep, 20	4,987,437	12.81%
30 Jun, 20	4,421,252	-14.65%
31 Mar, 20	5,180,161	88.98%
31 Dec, 19	2,741,122	-18.28%
30 Sep, 19	3,354,266	25.33%
30 Jun, 19	2,676,365	145.47%
31 Mar, 19	1,090,296	14219.62%
31 Dec, 18	7,614	-

Seelos Therapeutics (SEEL) has 21.87M shares outstanding as of 31 Mar 23, down -4.31% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 23	20.56%	-4.00%
31 Dec, 22	21.42%	-16.50%
30 Sep, 22	25.65%	-13.56%
30 Jun, 22	29.68%	-31.64%
31 Mar, 22	43.41%	9.69%
31 Dec, 21	39.57%	-14.67%
30 Sep, 21	46.38%	-21.58%
30 Jun, 21	59.14%	-40.86%
31 Mar, 21	100.00%	-
31 Dec, 20	100.00%	-
30 Sep, 20	100.00%	-
30 Jun, 20	100.00%	-
31 Mar, 20	100.00%	-
31 Dec, 19	100.00%	-
30 Sep, 19	100.00%	-
30 Jun, 19	100.00%	-
31 Mar, 19	100.00%	3287.19%
31 Dec, 18	2.95%	-

As of 31 Mar 23, Seelos Therapeutics is held by 20.56% institutional shareholders, representing a -4.00% negative growth compared to 31 Dec 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 23	10	-23.08%
31 Dec, 22	13	-23.53%
30 Sep, 22	17	-10.53%
30 Jun, 22	19	-26.92%
31 Mar, 22	26	-25.71%
31 Dec, 21	35	-7.89%
30 Sep, 21	38	52.00%
30 Jun, 21	25	108.33%
31 Mar, 21	12	71.43%
31 Dec, 20	7	16.67%
30 Sep, 20	6	20.00%
30 Jun, 20	5	-16.67%
31 Mar, 20	6	20.00%
31 Dec, 19	5	-16.67%
30 Sep, 19	6	-
30 Jun, 19	6	500.00%
31 Mar, 19	1	-
31 Dec, 18	-	-

10 institutional shareholders have increased their position in SEEL stock as of 31 Mar 23 compared to 13 in the previous quarter (a -23.08% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 23	21	-4.55%
31 Dec, 22	22	-8.33%
30 Sep, 22	24	-
30 Jun, 22	24	-11.11%
31 Mar, 22	27	22.73%
31 Dec, 21	22	-12.00%
30 Sep, 21	25	47.06%
30 Jun, 21	17	112.50%
31 Mar, 21	8	100.00%
31 Dec, 20	4	-20.00%
30 Sep, 20	5	-
30 Jun, 20	5	150.00%
31 Mar, 20	2	-50.00%
31 Dec, 19	4	100.00%
30 Sep, 19	2	100.00%
30 Jun, 19	1	-
31 Mar, 19	-	-
31 Dec, 18	-	-

21 institutional shareholders have reduced their position in SEEL stock as of 31 Mar 23 compared to 22 in the previous quarter (a -4.55% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 23	75	1.35%	21,865,016	-4.31%	20.56%	-4.00%	10	-23.08%	21	-4.55%
31 Dec, 22	74	1.37%	22,850,203	-16.02%	21.42%	-16.50%	13	-23.53%	22	-8.33%
30 Sep, 22	73	1.39%	27,207,513	-13.12%	25.65%	-13.56%	17	-10.53%	24	-
30 Jun, 22	72	-13.25%	31,315,916	-20.63%	29.68%	-31.64%	19	-26.92%	24	-11.11%
31 Mar, 22	83	-7.78%	39,455,693	-2.56%	43.41%	9.69%	26	-25.71%	27	22.73%
31 Dec, 21	90	-13.46%	40,494,190	-0.78%	39.57%	-14.67%	35	-7.89%	22	-12.00%
30 Sep, 21	104	7.22%	40,811,743	-0.07%	46.38%	-21.58%	38	52.00%	25	47.06%
30 Jun, 21	97	40.58%	40,838,763	63.25%	59.14%	-40.86%	25	108.33%	17	112.50%
31 Mar, 21	69	155.56%	25,016,141	233.72%	100.00%	-	12	71.43%	8	100.00%
31 Dec, 20	27	8.00%	7,496,228	50.30%	100.00%	-	7	16.67%	4	-20.00%
30 Sep, 20	25	-3.85%	4,987,437	12.81%	100.00%	-	6	20.00%	5	-
30 Jun, 20	26	23.81%	4,421,252	-14.65%	100.00%	-	5	-16.67%	5	150.00%
31 Mar, 20	21	50.00%	5,180,161	88.98%	100.00%	-	6	20.00%	2	-50.00%
31 Dec, 19	14	-30.00%	2,741,122	-18.28%	100.00%	-	5	-16.67%	4	100.00%
30 Sep, 19	20	33.33%	3,354,266	25.33%	100.00%	-	6	-	2	100.00%
30 Jun, 19	15	25.00%	2,676,365	145.47%	100.00%	-	6	500.00%	1	-
31 Mar, 19	12	1100.00%	1,090,296	14219.62%	100.00%	3287.19%	1	-	-	-
31 Dec, 18	1	-	7,614	-	2.95%	-	-	-	-	-

Seelos Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Dec 01, 2023	Golembiewski Michael Joseph	officer	Chief Financial Officer	P-Purchase	Buy	83,000	$1.21	$100.22K	86,450
Dec 01, 2023	Mehra Raj	director, officer	See Remarks	P-Purchase	Buy	75,757	$1.32	$100.00K	185,142
Dec 01, 2023	Mehra Raj	director, officer	See Remarks	P-Purchase	Buy	75,757	$1.32	$100.00K	75,757

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Dec 01, 2023	Golembiewski Michael Joseph	officer	Chief Financial Officer	P-Purchase	Buy	83,000	$1.21	$100.22K	86,450
Dec 01, 2023	Mehra Raj	director, officer	See Remarks	P-Purchase	Buy	75,757	$1.32	$100.00K	185,142
Dec 01, 2023	Mehra Raj	director, officer	See Remarks	P-Purchase	Buy	75,757	$1.32	$100.00K	75,757

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Mar 01, 2024	Golembiewski Michael Joseph	officer	Chief Financial Officer	A-Award	Buy	417	$1.10	$457.45	86,869
Jan 17, 2024	Mehra Raj	director, officer	See Remarks	A-Award	Buy	70,383	$1.41	$99.24K	70,383
Jan 17, 2024	Golembiewski Michael Joseph	officer	Chief Financial Officer	A-Award	Buy	24,537	$1.41	$34.60K	24,537
Jan 08, 2024	Pascoe Richard W	director	-	A-Award	Buy	1,666	$1.33	$2.22K	1,666
Jan 08, 2024	DALESANDRO MARGARET	director	-	A-Award	Buy	1,666	$1.33	$2.22K	1,666
Jan 08, 2024	Lian Brian	director	-	A-Award	Buy	1,666	$1.33	$2.22K	1,666
Jan 08, 2024	O'Connor Daniel J.	director	-	A-Award	Buy	1,666	$1.33	$2.22K	1,666
Dec 01, 2023	Golembiewski Michael Joseph	officer	Chief Financial Officer	P-Purchase	Buy	83,000	$1.21	$100.22K	86,450
Dec 01, 2023	Mehra Raj	director, officer	See Remarks	P-Purchase	Buy	75,757	$1.32	$100.00K	185,142
Dec 01, 2023	Mehra Raj	director, officer	See Remarks	P-Purchase	Buy	75,757	$1.32	$100.00K	75,757
Sep 01, 2023	Golembiewski Michael Joseph	officer	Chief Financial Officer	A-Award	Buy	12,500	$0.62	$7.72K	103,487
Mar 31, 2023	Mehra Raj	director, officer	See Remarks	A-Award	Buy	1,682,300	$0.69	$1.16M	1,682,300
Mar 31, 2023	Mehra Raj	director, officer	See Remarks	A-Award	Buy	200,000	$0.69	$138.00K	200,000
Mar 31, 2023	Golembiewski Michael Joseph	officer	Chief Financial Officer	A-Award	Buy	677,701	$0.69	$467.61K	677,701
Mar 31, 2023	Golembiewski Michael Joseph	officer	Chief Financial Officer	A-Award	Buy	88,030	$0.69	$60.74K	88,030
Mar 02, 2023	Golembiewski Michael Joseph	officer	Chief Financial Officer	A-Award	Buy	12,500	$0.67	$8.40K	90,987
Jan 05, 2023	Pascoe Richard W	director	-	A-Award	Buy	50,000	-	-	50,000
Jan 05, 2023	O'Connor Daniel J.	director	-	A-Award	Buy	50,000	-	-	50,000
Jan 05, 2023	DALESANDRO MARGARET	director	-	A-Award	Buy	50,000	-	-	50,000
Jan 05, 2023	Lian Brian	director	-	A-Award	Buy	50,000	-	-	50,000

The last insider buy of SEEL was made by Golembiewski Michael Joseph on Dec 01 2023, buying 83,000 shares at $1.21 per share (worth $100.22K).

Seelos Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	7	-	-
Q4 2023	3	-	-
Q3 2023	1	-	-
Q1 2023	9	-	-
Q2 2022	2	-	-
Q1 2022	8	-	-
Q3 2021	1	5	20.00%
Q1 2021	5	-	-
Q2 2020	3	-	-
Q1 2020	6	-	-
Q1 2019	8	3	266.67%
Q4 2018	-	2	-
Q3 2018	1	2	50.00%
Q1 2018	9	4	225.00%
Q3 2017	2	3	66.67%
Q2 2017	3	-	-
Q1 2017	8	3	266.67%
Q3 2016	5	-	-
Q2 2016	21	4	525.00%
Q1 2016	18	-	-

7 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Seelos Therapeutics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	-	-	-
Q4 2023	3	-	-
Q3 2023	-	-	-
Q1 2023	-	-	-
Q2 2022	2	-	-
Q1 2022	1	-	-
Q3 2021	-	-	-
Q1 2021	-	-	-
Q2 2020	-	-	-
Q1 2020	1	-	-
Q1 2019	-	-	-
Q4 2018	-	-	-
Q3 2018	-	-	-
Q1 2018	-	-	-
Q3 2017	2	-	-
Q2 2017	-	-	-
Q1 2017	-	-	-
Q3 2016	-	-	-
Q2 2016	-	-	-
Q1 2016	4	-	-

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Seelos Therapeutics's stocks.

Seelos Therapeutics Peer Ownership

Ticker	Company
SLNO	Soleno Therapeutics, Inc.
ATAI	Atai Life Sciences N.V.
PULM	Pulmatrix, Inc.
EWTX	Edgewise Therapeutics, Inc.
HSTO	Histogen Inc.
GHRS	GH Research PLC
MNMD	Mind Medicine (MindMed) Inc.
CAPR	Capricor Therapeutics, Inc.
DFFN	CervoMed Inc.
AKTX	Akari Therapeutics, Plc
ITOS	iTeos Therapeutics, Inc.
TPST	Tempest Therapeutics, Inc.
ENTX	Entera Bio Ltd.
MOLN	Molecular Partners AG
OPT	Opthea Limited
ELYM	Eliem Therapeutics, Inc.

SEEL Ownership FAQ

Who Owns Seelos Therapeutics?

Seelos Therapeutics is owned by institutional shareholders (20.56%), insiders (0.49%), and public (78.95%). The largest institutional shareholder of Seelos Therapeutics is GENDELL JEFFREY L (4.77% of total shares) and the top mutual fund owner is AdvisorShares Trust (0.15% of total shares).

Who are the major institutional shareholders of Seelos Therapeutics?

Seelos Therapeutics's major institutional shareholders are GENDELL JEFFREY L, VANGUARD GROUP INC, BLACKROCK INC., MIRAE ASSET GLOBAL INVESTMENTS CO., LTD., and GEODE CAPITAL MANAGEMENT, LLC. The top five shareholders own together 13.47% of the company's share outstanding.

How many Seelos Therapeutics shareholders are there?

As of Mar 2023, there are 75 institutional shareholders of Seelos Therapeutics.

What percentage of Seelos Therapeutics is owned by GENDELL JEFFREY L?

GENDELL JEFFREY L owns 5.07M shares of Seelos Therapeutics, representing 4.77% of the company's total shares outstanding, valued at $3.5B (as of Mar 2023).

What percentage of Seelos Therapeutics is owned by VANGUARD GROUP INC?

As of Mar 2023, VANGUARD GROUP INC holds 5.02M shares of Seelos Therapeutics (SEEL), compromising 4.72% of the company, valued at $3.47B.

What percentage of Seelos Therapeutics is owned by BLACKROCK INC?

BLACKROCK INC is the third largest holder of Seelos Therapeutics. The company owns 1.66M of the company's shares outstanding (worth $1.15B).